ReviewInternational journal of cancer2026
Colorectal Cancer Screening in Hereditary and Familial High-Risk Populations: Best Practices and Future Directions.
Review in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A case of Lynch syndrome diagnosed after nine metachronous cancers detected over 35 years.Clinical journal of gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Colorectal cancer (CRC) remains a leading cause of cancer-related morbidity and mortality worldwide yet is largely preventable through effective screening and surveillance. While most CRC cases are sporadic, a substantial proportion occur in individuals at increased risk due to hereditary cancer syndromes or family history who require tailored screening strategies different from population-based approaches with respect to age of initiation, surveillance intervals, and modality. This review summarizes current evidence on CRC risk across higher risk groups, including Lynch syndrome, polyposis syndromes, carriers of moderate-penetrance genes, and individuals with a family history of CRC. Efficacy of colonoscopic surveillance and the potential roles of emerging biomarker tests and artificial intelligence-assisted technologies for detection of colorectal neoplasia are discussed. Current CRC surveillance guidelines, quality metrics and adherence in higher risk groups are reviewed. As research in genomics, biomarkers, microbiome, and artificial intelligence evolves, personalized risk-based screening strategies hold promise for optimizing CRC prevention. High-quality, population-specific data will be essential to refine surveillance intensity, improve adherence, and reduce CRC burden in higher risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.